Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

FDA fast-tracks Astellas' Rydapt rival

FDA fast-tracks Astellas' Rydapt rival If approved, the Japanese pharma group would see its drug not only compete with Rydapt - the first new drug for AML in more than 25 years - but also with Daiichi

Xarelto no better than aspirin in secondary stroke study

Xarelto no better than aspirin in secondary stroke study For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s

Novartis gets EU nod for leukaemia drug Rydapt

Novartis gets EU nod for leukaemia drug Rydapt The FLT3 inhibitor adds to its US approval in AML

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics